Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
